Betaliq

Executive Summary

Betaliq is a private, Phase 3 ophthalmology company redefining topical glaucoma therapies through its exclusive access to Novaliq's innovative EyeSol® water-free drug delivery platform. Founded in 2018 via a strategic collaboration between BLP Management Group and Novaliq GmbH, the company aims to improve the safety and efficacy of topical ophthalmic treatments. EyeSol technology addresses key limitations of conventional aqueous formulations, such as poor drug solubility and corneal penetration, potentially enabling better intraocular pressure control and reduced side effects. Betaliq's initial focus is on building a robust glaucoma therapy portfolio, leveraging this proprietary platform to address a large and growing global market.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line data readout for lead glaucoma candidate60% success
• Q1 2027New Drug Application (NDA) submission to FDA50% success
• Q2 2026Announcement of strategic partnership for ex-US commercialization rights40% success